Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.50 |
| ▸ | CNR2 | P34972 | 2/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4477253 | 0.87 | DPP4 (0.50) | CNR1CNR2DPP4 | |
| SCHEMBL4559521 | 0.87 | CNR1 (0.52) | CNR1CNR2DPP4 | |
| SCHEMBL4480277 | 0.79 | ALDH1A1 (0.51) | CNR1CNR2 | |
| SCHEMBL5043907 | 0.76 | CNR1 (0.65) | CNR1CNR2 | |
| SCHEMBL2847142 | 0.73 | AHR (0.40) | CNR1CNR2DPP4HSD11B1 | |
| SCHEMBL4477519 | 0.72 | CNR1 (0.57) | CNR1CNR2 | |
| SCHEMBL4911607 | 0.69 | HSD11B1 (0.43) | DPP4HSD11B1OPRL1 | |
| SCHEMBL5041885 | 0.68 | CNR1 (0.60) | CNR1CNR2 | |
| SCHEMBL2933108 | 0.67 | AHR (0.67) | HSD11B1 | |
| SCHEMBL2850192 | 0.67 | ESR1 (0.41) | CNR1CNR2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618991-B2 | Heterocyclic derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2009-11-17 | — | — | US | disclosed |
| US-20080269303-A1 | HETEROCYCLIC DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269303-A1 | HETEROCYCLIC DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | CYP11B2, CYP11B1, NQO1 | CNR1 12/4885CNR2 38/4885DPP4 1868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.